Dano Pharmaceutical Technology

Dano Pharma is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for infectious and metabolic diseases. The company utilizes a proprietary multi-target drug design platform to create small molecule drugs that address unmet medical needs, particularly in the areas of gastrointestinal and device-associated infections. Its lead candidate, TNP-2198, is a first-in-class multi-target drug designed to treat Helicobacter pylori infections and is currently in late-stage clinical development. Dano Pharma aims to provide more effective and safer treatment options to combat the rising challenge of antimicrobial resistance.